➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
AstraZeneca
Colorcon
Mallinckrodt

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ODOMZO

« Back to Dashboard

All Clinical Trials for Odomzo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02086552 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting National Cancer Institute (NCI) Phase 2 2014-01-01 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
NCT02086552 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting Novartis Pharmaceuticals Phase 2 2014-01-01 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
NCT02086552 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting Mayo Clinic Phase 2 2014-01-01 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Odomzo

Condition Name

Condition Name for Odomzo
Intervention Trials
Invasive Carcinoma 1
Progressive Disease 1
Unresectable Malignant Solid Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Odomzo
Intervention Trials
Carcinoma 4
Skin Neoplasms 3
Carcinoma, Basal Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Odomzo

Trials by Country

Trials by Country for Odomzo
Location Trials
United States 6
Italy 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Odomzo
Location Trials
Minnesota 3
Florida 1
Arizona 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Odomzo

Clinical Trial Phase

Clinical Trial Phase for Odomzo
Clinical Trial Phase Trials
Phase 2 3
Phase 1 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Odomzo
Clinical Trial Phase Trials
Recruiting 3
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Odomzo

Sponsor Name

Sponsor Name for Odomzo
Sponsor Trials
National Cancer Institute (NCI) 4
Mayo Clinic 3
Novartis Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Odomzo
Sponsor Trials
Other 6
NIH 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.